N-glycosylation (sugar modification) of peptide hormone receptors is critical for proper ligand binding and activation, with implications for drug development targeting GLP-1, amylin, and related receptors.
Critical for most class B1 GPCRsN-glycosylation is essential for normal receptor function across the family that includes GLP-1, GIP, amylin, calcitonin, and secretin receptors
What the researchers found
The review reveals that N-glycosylation enhances pharmacodynamic properties of class B1 GPCRs including receptor-ligand binding and activation potency. Key findings by receptor type:
- Calcitonin and amylin receptors: N-glycosylation apparently enhanced binding affinity of peptide ligands, with specific critical N-glycosylation sites identified
- GIP and secretin receptors: Also have critical individual N-glycosylation sites that drive the whole glycosylation effect
- GLP-1 and CRF1 receptors: Each glycosylation site collectively contributes to the overall effect, rather than one site being dominant
- Calcitonin gene-related peptide receptor: Has identified critical N-glycosylation sites
The review also addresses potential mechanisms by which sugar modifications enhance peptide ligand binding affinity at the molecular level.
Why it matters
Many of today's blockbuster peptide drugs — including semaglutide (GLP-1), tirzepatide (GIP/GLP-1), and calcitonin — work by binding to class B1 GPCRs. Understanding that sugar modifications on these receptors significantly affect how peptide drugs bind and activate them is essential for accurately evaluating drug potency and designing better therapeutics.
How the study worked
This is a narrative review summarizing published research on N-glycosylation effects across class B1 GPCR family members. The authors focused on three functional parameters: cell-surface receptor expression, ligand binding affinity, and receptor activation potency. They compared glycosylation patterns and functional dependencies across multiple receptor systems.
What this study cannot tell us
The review notes that several class B1 GPCR family members remain unexplored regarding their N-glycosylation effects. Most studies reviewed used cell-based systems that may not perfectly replicate in vivo glycosylation patterns. The mechanisms by which glycosylation enhances binding remain incompletely understood.
How to read the evidence
This is a narrative review synthesizing published biochemical and pharmacological studies. It provides a useful overview of the field but does not generate new experimental evidence.
When this study was published
Published in 2025, this review captures the current understanding of glycosylation effects on peptide hormone receptors, relevant to the rapidly expanding field of peptide therapeutics.
The bigger picture
As the peptide drug market expands rapidly — with GLP-1 agonists alone generating tens of billions in annual revenue — understanding the molecular details of receptor interaction becomes increasingly important. This review highlights a often-overlooked factor (glycosylation) that could affect drug development screening and lead optimization for the next generation of peptide therapeutics.
Questions still open
- How does individual patient variation in receptor glycosylation affect their response to peptide drugs like semaglutide?
- Could glycosylation differences explain some of the variability in GLP-1 agonist effectiveness across patients?
- Should drug screening assays be redesigned to better account for receptor glycosylation states?
Common questions
What is N-glycosylation and why does it matter for peptide drugs?
Which popular peptide drugs are affected by receptor glycosylation?
Read the original research
N-glycosylation effects on the function of class B1 G protein-coupled receptors.
Carbohydrate research, 557, 109641
Citation
Lee, Sangmin; Jin, Jeongwoo; Song, Hyeseon; Jang, Jaehyeok. (2025). N-glycosylation effects on the function of class B1 G protein-coupled receptors.. Carbohydrate research, 557, 109641. https://doi.org/10.1016/j.carres.2025.109641